Pharmacotherapy and Intensive Treatment of Drug Abuse - 1

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00000217

First Posted: September 21, 1999

Last Update Posted: April 16, 2015

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Collaborators:

National Institute on Drug Abuse (NIDA)

VA Office of Research and Development

Information provided by (Responsible Party):

University of Kansas Medical Center ( University of Kansas )

Purpose

The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.

Condition	Intervention	Phase
Cocaine-Related Disorders Substance-Related Disorders	Drug: Carbamazepine	Phase 2


Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Pharmacotherapy and Intensive Treatment of Drug Abuse

Resource links provided by NLM:

Drug Information available for: Carbamazepine

U.S. FDA Resources

Further study details as provided by University of Kansas Medical Center ( University of Kansas ):

Primary Outcome Measures:

Drug use
Effectiveness of medication
Level of pharm
Retention
Depression, anxiety


Study Start Date:	September 1990
Primary Completion Date:	October 1996 (Final data collection date for primary outcome measure)

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 60 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000217

Locations


United States, Missouri
University of Kansas
Kansas City, Missouri, United States, 64128

Sponsors and Collaborators

University of Kansas

National Institute on Drug Abuse (NIDA)

VA Office of Research and Development

Investigators


Principal Investigator:	William Haning, M.D.	University of Kansas

More Information

Publications:

J Addictive Dis. 13; 1994


Responsible Party:	University of Kansas
ClinicalTrials.gov Identifier:	NCT00000217 History of Changes
Other Study ID Numbers:	NIDA-06954-1 R18DA006954 ( U.S. NIH Grant/Contract ) R18-06954-1
First Submitted:	September 20, 1999
First Posted:	September 21, 1999
Last Update Posted:	April 16, 2015
Last Verified:	April 2015

Keywords provided by University of Kansas Medical Center ( University of Kansas ):


drug abuse

Additional relevant MeSH terms:


Disease Substance-Related Disorders Cocaine-Related Disorders Pathologic Processes Chemically-Induced Disorders Mental Disorders Carbamazepine Anticonvulsants Antimanic Agents Tranquilizing Agents	Central Nervous System Depressants Physiological Effects of Drugs Psychotropic Drugs Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Cytochrome P-450 CYP3A Inducers Cytochrome P-450 Enzyme Inducers Molecular Mechanisms of Pharmacological Action

To Top